Fluorinated benzamide neuroleptics—III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2,3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer
- 1 April 1995
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 22 (3), 283-296
- https://doi.org/10.1016/0969-8051(94)00117-3
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Evaluation of 5‐[18F]Fluoropropylepidepride as a potential pet radioligand for imaging dopamine D2 receptorsSynapse, 1993
- Positron-Emitting N-(18F)Fluoroalkyl and (18F)Fluoropyrrolidinyl Analogues of Eticlopride as Potential in Vivo Radioligands for Dopamine D2 Receptors.CHEMICAL & PHARMACEUTICAL BULLETIN, 1992
- Fluorinated benzamide neuroleptics—2. Synthesis and radiosynthesis of (S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-3-substituted-2-methoxybenzamidesInternational Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, 1991
- Antidopaminergic effects of the stereoisomers of N-[(1-alkyl-2-pyrrolidinyl)methyl]-5-sulfamoylbenzamides and -2,3-dihydro-benzofuran-7-carboxamidesJournal of Medicinal Chemistry, 1991
- Optically active benzamides as predictive tools for mapping the dopamine D2 receptorEuropean Journal of Pharmacology: Molecular Pharmacology, 1990
- Use of Diethylaminosulfur Trifluoride in an Efficient Synthesis of (S)-N-[(1-Ethyl-2-Pyrrolidinyl)Methyl]-5-(3-Fluoropropyl-2-MethoxybenzamideJournal of Fluorine Chemistry, 1990
- Potential antipsychotic agents. Part 8. Antidopaminergic properties of a potent series of 5-substituted (−)-(S)-N-[(1-ethylpyrrolidin-2-yl)methyl]-2,3-dimethoxybcnzaimides. Synthesisviacommon lithio intermediatesHelvetica Chimica Acta, 1990
- Analysis of radioligand binding experimentsJournal of Pharmacological Methods, 1985
- Potential neuroleptic agents. 3. Chemistry and antidopaminergic properties of substituted 6-methoxysalicylamidesJournal of Medicinal Chemistry, 1985
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973